Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practiceReportar como inadecuado




Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Hematology and Oncology

, 8:92

First Online: 28 July 2015Received: 24 June 2015Accepted: 02 July 2015DOI: 10.1186-s13045-015-0183-8

Cite this article as: Goel, G.
& Sun, W.
J Hematol Oncol 2015 8: 92.
doi:10.1186-s13045-015-0183-8

Abstract

The recent FDA approval of ramucirumab RAISE trial has added a third agent to our existing armamentarium of angiogenesis inhibitors bevacizumab and ziv-aflibercept for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

KeywordsAnti-angiogenesis Ramucirumab Bevacizumab Ziv-aflibercept Colorectal cancer  Download fulltext PDF



Autor: Gaurav Goel - Weijing Sun

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados